Data is not available at this time.
Option Care Health, Inc. operates as a leading provider of home and alternate-site infusion therapy services in the U.S. healthcare sector. The company specializes in delivering cost-effective, high-quality clinical solutions for patients with acute and chronic conditions, including immune deficiencies, bleeding disorders, and neurological disorders. Its revenue model is driven by reimbursements from payers such as Medicare, Medicaid, and private insurers, supported by a scalable platform that optimizes care coordination and operational efficiency. Option Care Health distinguishes itself through its national footprint, clinical expertise, and integrated pharmacy services, positioning it as a trusted partner for healthcare providers and payers. The company benefits from long-term industry tailwinds, including the shift toward home-based care and the growing prevalence of chronic diseases. Its competitive moat lies in its regulatory compliance, proprietary protocols, and ability to manage complex therapies, which create barriers to entry for smaller players.
Option Care Health reported revenue of $4.998 billion for FY 2024, reflecting steady demand for its infusion services. Net income stood at $211.8 million, with diluted EPS of $1.23, indicating disciplined cost management. Operating cash flow of $323.4 million underscores the company’s ability to convert earnings into liquidity, though capital expenditures were negligible, suggesting limited near-term growth investments.
The company demonstrates solid earnings power, with a net margin of approximately 4.2%. Its capital efficiency is supported by a scalable asset-light model, as evidenced by robust operating cash flow relative to net income. The absence of capital expenditures in the period suggests a focus on optimizing existing infrastructure rather than expansion.
Option Care Health maintains a balanced financial position, with $412.6 million in cash and equivalents against $1.218 billion in total debt. The liquidity position appears adequate, though leverage metrics warrant monitoring given the debt load. The lack of dividends aligns with a reinvestment strategy aimed at sustaining organic growth.
Revenue growth is likely tied to demographic trends and payer preferences for home-based care. The company has not instituted a dividend, prioritizing reinvestment in clinical capabilities and potential M&A. Future growth may hinge on expanding service lines and geographic penetration, supported by industry tailwinds.
With a diluted EPS of $1.23 and a scalable model, the market likely prices OPCH on growth potential rather than current earnings. Valuation multiples should reflect the company’s position in a fragmented industry with consolidation opportunities, though competitive pressures and reimbursement risks remain key considerations.
Option Care Health’s strategic advantages include its national scale, clinical expertise, and payer relationships. The outlook is positive, supported by healthcare cost containment trends favoring home infusion. Execution risks include regulatory changes and integration challenges from acquisitions, but the company is well-positioned to capitalize on industry shifts.
10-K filing, CIK 0001014739
show cash flow forecast
Fiscal year | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 | 2034 | 2035 | 2036 | 2037 | 2038 | 2039 | 2040 | 2041 | 2042 | 2043 | 2044 | 2045 | 2046 | 2047 | 2048 | 2049 | |
INCOME STATEMENT | ||||||||||||||||||||||||||
Revenue growth rate, % | NaN | |||||||||||||||||||||||||
Revenue, $ | NaN | |||||||||||||||||||||||||
Variable operating expenses, $m | NaN | |||||||||||||||||||||||||
Fixed operating expenses, $m | NaN | |||||||||||||||||||||||||
Total operating expenses, $m | NaN | |||||||||||||||||||||||||
Operating income, $m | NaN | |||||||||||||||||||||||||
EBITDA, $m | NaN | |||||||||||||||||||||||||
Interest expense (income), $m | NaN | |||||||||||||||||||||||||
Earnings before tax, $m | NaN | |||||||||||||||||||||||||
Tax expense, $m | NaN | |||||||||||||||||||||||||
Net income, $m | NaN | |||||||||||||||||||||||||
BALANCE SHEET | ||||||||||||||||||||||||||
Cash and short-term investments, $m | NaN | |||||||||||||||||||||||||
Total assets, $m | NaN | |||||||||||||||||||||||||
Adjusted assets (=assets-cash), $m | NaN | |||||||||||||||||||||||||
Average production assets, $m | NaN | |||||||||||||||||||||||||
Working capital, $m | NaN | |||||||||||||||||||||||||
Total debt, $m | NaN | |||||||||||||||||||||||||
Total liabilities, $m | NaN | |||||||||||||||||||||||||
Total equity, $m | NaN | |||||||||||||||||||||||||
Debt-to-equity ratio | NaN | |||||||||||||||||||||||||
Adjusted equity ratio | NaN | |||||||||||||||||||||||||
CASH FLOW | ||||||||||||||||||||||||||
Net income, $m | NaN | |||||||||||||||||||||||||
Depreciation, amort., depletion, $m | NaN | |||||||||||||||||||||||||
Funds from operations, $m | NaN | |||||||||||||||||||||||||
Change in working capital, $m | NaN | |||||||||||||||||||||||||
Cash from operations, $m | NaN | |||||||||||||||||||||||||
Maintenance CAPEX, $m | NaN | |||||||||||||||||||||||||
New CAPEX, $m | NaN | |||||||||||||||||||||||||
Total CAPEX, $m | NaN | |||||||||||||||||||||||||
Free cash flow, $m | NaN | |||||||||||||||||||||||||
Issuance/(repurchase) of shares, $m | NaN | |||||||||||||||||||||||||
Retained Cash Flow, $m | NaN | |||||||||||||||||||||||||
Pot'l extraordinary dividend, $m | NaN | |||||||||||||||||||||||||
Cash available for distribution, $m | NaN | |||||||||||||||||||||||||
Discount rate, % | NaN | |||||||||||||||||||||||||
PV of cash for distribution, $m | NaN | |||||||||||||||||||||||||
Current shareholders' claim on cash, % | NaN |